Neonatal Drug Therapy Manual

Amphotericin B

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Updated March 5, 2024 - 2:32pm

Alternate Name(s): 
Fungizone
Classification: 
Antifungal
Original Date: 
March 1992
Revised Date: 
August 2003
Indications: 
  • Treatment of systemic fungal infections and severe superficial mycoses
Administration: 
  • IV intermittent infusion :       
    • CHEO: over 2 - 6 hours
    • TOH: over 4 hours
Dosage: 
  • 0.5 - 1 mg/kg/day once daily
Side Effects: 
  • CNS: fever
  • CVS: hypotension
  • Endocrine and metabolic: hypokalemia, hypomagnesemia
  • Hematologic: anemia, leukopenia, thrombocytopenia
  • Hepatic: acute hepatic failure, jaundice; AST, ALT and bilirubin elevated
  • Local: phlebitis
  • Renal: renal failure, renal tubular acidosis
Parameters to Monitor: 
  • BUN and serum creatinine
  • Serum potassium and serum magnesium
  • Electrolytes
  • Liver function
  • CBC
Reconstitution and Stability: 
  • Amphotericin B 50 mg
    • Add 10 mL SWFI. Take 1 mL (5 mg) and add to 49 mL D5W
    • Final concentration: 0.1 mg/mL
Compatibility: 

- Solutions Compatible: D5W, D10W

Incompatible: all saline solutions as precipitation will occur.  Do not mix with other drugs

References: 

-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 9th-11th Editions. Hudson: Lexi-Comp Inc.; 2002-2004.

-Trissel LA. Handbook on Injectable Drugs. 12th-13th Editions. Bethesda: American Society of Health-System Pharmacists; 2003-2005.

-Roy R, Griffiths K, editors. The formulary-The Hospital for Sick Children. 21st-22nd Editions. Toronto: Department of Pharmacy; 2002-2004.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.